Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration

被引：0
|
作者：
Maruyama-Inoue, Maiko [1 ]
Chin, Jacob Yuhang [2 ]
Kadonosono, Kazuaki [1 ]
机构：
[1] Yokohama City Univ, Med Ctr, Dept Ophthalmol, 4-57 Urafune Cho,Minami Ku, Yokohama, Kanagawa 2320024, Japan
[2] Tan Tock Seng Hosp, Natl Healthcare Grp, Eye Inst, Singapore, Singapore
来源：
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | 2024年
关键词：
D O I：
10.1007/s00417-024-06516-8
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：3735 / 3736
页数：2
相关论文
共 50 条
  • [21] A case of recalcitrant neovascular wet age-related macular degeneration treated with Intravitreal Brolucizumab
    Panigrahi, Pradeep Kumar
    PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2021, 35
  • [22] Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration
    Book, Marius
    Ziegler, M.
    Rothaus, K.
    Faatz, H.
    Gutfleisch, M.
    Spital, G.
    Lommatzsch, A.
    Pauleikhoff, D.
    OPHTHALMOLOGE, 2022, 119 (03): : 258 - 264
  • [23] The effect of intravitreal brolucizumab on choroidal thickness in patients with neovascular age-related macular degeneration
    Bae, Ki Woong
    Kim, Dong Ik
    Hwang, Daniel Duck-Jin
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [24] The effect of intravitreal brolucizumab on choroidal thickness in patients with neovascular age-related macular degeneration
    Ki Woong Bae
    Dong Ik Kim
    Daniel Duck-Jin Hwang
    Scientific Reports, 12
  • [25] Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration
    Kikuchi, Yusuke
    Kawczynski, Michael G.
    Anegondi, Neha
    Neubert, Ales
    Dai, Jian
    Ferrara, Daniela
    Quezada-Ruiz, Carlos
    OPHTHALMOLOGY SCIENCE, 2024, 4 (02):
  • [26] COST-EFFECTIVENESS OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CANADA
    Buhrer, C.
    Paulo, T.
    Diles, D.
    VALUE IN HEALTH, 2022, 25 (12) : S111 - S112
  • [27] Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration
    Hikaru Ota
    Jun Takeuchi
    Yuyako Nakano
    Etsuyo Horiguchi
    Yosuke Taki
    Yasuki Ito
    Hiroko Terasaki
    Koji M. Nishiguchi
    Keiko Kataoka
    Japanese Journal of Ophthalmology, 2022, 66 : 278 - 284
  • [28] Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration
    Ota, Hikaru
    Takeuchi, Jun
    Nakano, Yuyako
    Horiguchi, Etsuyo
    Taki, Yosuke
    Ito, Yasuki
    Terasaki, Hiroko
    Nishiguchi, Koji M.
    Kataoka, Keiko
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2022, 66 (03) : 278 - 284
  • [29] Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial
    Dugel, Pravin U.
    Jaffe, Glenn J.
    Sallstig, Peter
    Warburton, James
    Weichselberger, Andreas
    Wieland, Mark
    Singerman, Lawrence
    OPHTHALMOLOGY, 2017, 124 (09) : 1296 - 1304
  • [30] Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration
    Book, Marius
    Ziegler, M.
    Rothaus, K.
    Faatz, H.
    Gutfleisch, M.
    Spital, G.
    Lommatzsch, A.
    Pauleikhoff, D.
    OPHTHALMOLOGIE, 2022, 119 (03): : 258 - 264
12345